Processa Pharmaceuticals Inc SEC Filings

Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA), amended a prior filing to report ownership of 28,000 restricted stock units. The RSUs convert to common stock and are structured to vest 50% on July 16, 2025, with the remaining 50% contingent on achievement of specified performance criteria. The amendment retracts an earlier Form 4 that was filed in error. The reported transaction date is July 24, 2025, and the amended Form 4 was signed by attorney-in-fact on September 18, 2025.

Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), filed an amended Form 4 to correct prior reporting of her restricted stock and resulting direct beneficial ownership. The amendment discloses an acquisition code A for 31,206 shares of restricted stock acquired with a $0 price and underlying 31,206 shares of common stock. After the correction, Ms. Pannu directly beneficially owns 36,275 shares of common stock. The restricted shares are subject to vesting and will vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. The filing states the amendment retracts a prior Form 4 that was filed in error and corrects the beneficially owned shares previously reported.

Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), filed an amended Form 4 to correct prior reporting of her restricted stock and resulting direct beneficial ownership. The amendment discloses an acquisition code A for 31,206 shares of restricted stock acquired with a $0 price and underlying 31,206 shares of common stock. After the correction, Ms. Pannu directly beneficially owns 36,275 shares of common stock. The restricted shares are subject to vesting and will vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. The filing states the amendment retracts a prior Form 4 that was filed in error and corrects the beneficially owned shares previously reported.

Processa Pharmaceuticals (PCSA) reporting person George K. Ng amended a prior Form 4 to correct an earlier filing error. The amendment shows Mr. Ng is both a director and the Chief Executive Officer. The filing discloses indirect beneficial ownership of 87,200 shares of common stock held through warrants and 20,000 shares held by the Ng Cha Family Trust, as well as separate warrant holdings converting into 87,200 and 43,600 common shares at a $0.65 exercise price expiring 01/29/2030. The earliest transaction date listed is 07/24/2025, and the amendment notes the prior Form 4 was filed in error.

Processa Pharmaceuticals (PCSA) reporting person George K. Ng amended a prior Form 4 to correct an earlier filing error. The amendment shows Mr. Ng is both a director and the Chief Executive Officer. The filing discloses indirect beneficial ownership of 87,200 shares of common stock held through warrants and 20,000 shares held by the Ng Cha Family Trust, as well as separate warrant holdings converting into 87,200 and 43,600 common shares at a $0.65 exercise price expiring 01/29/2030. The earliest transaction date listed is 07/24/2025, and the amendment notes the prior Form 4 was filed in error.

Processa Pharmaceuticals, Inc. (PCSA) amended a prior Form 4 to correct reported insider holdings for reporting person Neal James R, who is identified as a director. The filing shows restricted stock granted with $0 price that vested subject to the earlier of June 28, 2025 or the next annual meeting, and records an acquisition of 31,206 restricted shares. The filing reports 36,275 common shares beneficially owned following the reported transactions. The amendment states it was filed to retract a prior Form 4 that was filed in error and to correct the beneficially owned shares previously reported on a Form 4 filed September 18, 2024. The form was signed by an attorney-in-fact on behalf of the reporting person.

Processa Pharmaceuticals, Inc. (PCSA) amended a prior Form 4 to correct reported insider holdings for reporting person Neal James R, who is identified as a director. The filing shows restricted stock granted with $0 price that vested subject to the earlier of June 28, 2025 or the next annual meeting, and records an acquisition of 31,206 restricted shares. The filing reports 36,275 common shares beneficially owned following the reported transactions. The amendment states it was filed to retract a prior Form 4 that was filed in error and to correct the beneficially owned shares previously reported on a Form 4 filed September 18, 2024. The form was signed by an attorney-in-fact on behalf of the reporting person.

Processa Pharmaceuticals insider amendment reports a corrected sale and existing family trust holdings. The filing amends a prior Form 4 to retract an earlier filing error and discloses a disposition of 38,727 shares of common stock reported as a sale. Following the reported transaction the reporting person is shown as beneficially owning 43,500 shares indirectly through the Lin Family Trust. The reporting person is an officer (Chief Business - Strategy Officer) and a director of the company. The amendment clarifies prior reporting and does not include derivative transactions or exercise details.

Processa Pharmaceuticals insider amendment reports a corrected sale and existing family trust holdings. The filing amends a prior Form 4 to retract an earlier filing error and discloses a disposition of 38,727 shares of common stock reported as a sale. Following the reported transaction the reporting person is shown as beneficially owning 43,500 shares indirectly through the Lin Family Trust. The reporting person is an officer (Chief Business - Strategy Officer) and a director of the company. The amendment clarifies prior reporting and does not include derivative transactions or exercise details.

Form 4/A filed for Processa Pharmaceuticals, Inc. (PCSA) amends earlier reporting. The reporting person is Sian Bigora, identified as Chief Development Officer and Director. The earliest transaction date reported is 07/24/2025, with an amendment date of 07/28/2025 and a signature entry dated 09/18/2025. The filing shows a disposition of 33,626 shares of common stock and continued beneficial ownership of 6,668 shares held indirectly through CorLyst, LLC. The amendment states it was filed to retract a prior Form 4 that was filed in error. The document discloses insider role, the specific share disposition, and the indirect ownership vehicle.

Form 4/A filed for Processa Pharmaceuticals, Inc. (PCSA) amends earlier reporting. The reporting person is Sian Bigora, identified as Chief Development Officer and Director. The earliest transaction date reported is 07/24/2025, with an amendment date of 07/28/2025 and a signature entry dated 09/18/2025. The filing shows a disposition of 33,626 shares of common stock and continued beneficial ownership of 6,668 shares held indirectly through CorLyst, LLC. The amendment states it was filed to retract a prior Form 4 that was filed in error. The document discloses insider role, the specific share disposition, and the indirect ownership vehicle.

Processa Pharmaceuticals director Khoso Baluch amended a prior Form 4 to correct reported insider holdings and retract an earlier erroneous filing. The amendment discloses a restricted stock grant of 31,206 shares that vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, and states 36,275 shares as the amount of common stock beneficially owned following the reported transactions. The filing identifies the reporting person as a director and shows an earliest transaction date of 07/24/2025, an amendment date of 07/28/2025, and a signature date of 09/18/2025. The amendment states it was filed to correct the beneficially owned shares reported on a Form 4 filed September 18, 2024, and to retract that prior Form 4 which was filed in error.

Processa Pharmaceuticals director Khoso Baluch amended a prior Form 4 to correct reported insider holdings and retract an earlier erroneous filing. The amendment discloses a restricted stock grant of 31,206 shares that vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, and states 36,275 shares as the amount of common stock beneficially owned following the reported transactions. The filing identifies the reporting person as a director and shows an earliest transaction date of 07/24/2025, an amendment date of 07/28/2025, and a signature date of 09/18/2025. The amendment states it was filed to correct the beneficially owned shares reported on a Form 4 filed September 18, 2024, and to retract that prior Form 4 which was filed in error.

Processa Pharmaceuticals, Inc. filed an amended current report to document shareholder approval of a major change to its capital structure. Effective September 12, 2025, the company amended its Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 1,000,000,000 shares. This amendment had been approved at a Special Meeting of Shareholders held on September 11, 2025.

At the Special Meeting, 17,127,838 shares of common stock were present in person or by proxy out of 50,349,149 shares entitled to vote as of the August 7, 2025 record date, satisfying the quorum requirement. Shareholders approved the Charter Proposal to increase authorized shares, as well as proposals relating to a reverse stock split, an equity incentive plan and an adjournment proposal, although adjournment was ultimately not needed.

Processa Pharmaceuticals, Inc. filed an amended current report to document shareholder approval of a major change to its capital structure. Effective September 12, 2025, the company amended its Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 1,000,000,000 shares. This amendment had been approved at a Special Meeting of Shareholders held on September 11, 2025.

At the Special Meeting, 17,127,838 shares of common stock were present in person or by proxy out of 50,349,149 shares entitled to vote as of the August 7, 2025 record date, satisfying the quorum requirement. Shareholders approved the Charter Proposal to increase authorized shares, as well as proposals relating to a reverse stock split, an equity incentive plan and an adjournment proposal, although adjournment was ultimately not needed.

Processa Pharmaceuticals, Inc. filed an amended current report to document shareholder approval of a major change to its capital structure. Effective September 12, 2025, the company amended its Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 1,000,000,000 shares. This amendment had been approved at a Special Meeting of Shareholders held on September 11, 2025.

At the Special Meeting, 17,127,838 shares of common stock were present in person or by proxy out of 50,349,149 shares entitled to vote as of the August 7, 2025 record date, satisfying the quorum requirement. Shareholders approved the Charter Proposal to increase authorized shares, as well as proposals relating to a reverse stock split, an equity incentive plan and an adjournment proposal, although adjournment was ultimately not needed.

Processa Pharmaceuticals, Inc. filed an update on its shareholder meeting logistics. The company convened a Special Shareholder Meeting on September 2, 2025, in Pasadena, California, but adjourned it and initially planned to reconvene on September 12, 2025, in Vero Beach, Florida. It now plans to reconvene the meeting on September 11, 2025, at 10:30 a.m. ET at its corporate office in Vero Beach, Florida.

The record date for the meeting remains August 7, 2025, meaning only stockholders of record at the close of business on that date may vote at the reconvened meeting. Stockholders who already submitted proxies or voted and do not wish to change their vote are not required to take any further action. The proposals for the meeting are unchanged, and related proxy materials remain available through the SEC’s website.

Processa Pharmaceuticals, Inc. held a Special Shareholder Meeting on September 2, 2025 but adjourned it without conducting any business because there were not enough shares present or represented by proxy to constitute a quorum. The meeting is scheduled to reconvene on September 12, 2025 at 5:00 PM ET in Vero Beach, Florida. The record date remains August 7, 2025, so only stockholders of record as of that date may vote at the reconvened meeting. Stockholders who have already voted and do not wish to change their vote do not need to take any further action, and all proposals for the meeting remain unchanged.